Germany: Merck KGaA strengthens CDMO offering with US$780m Exelead acquisition

Darmstadt-based German multinational science and technology company, Merck KGaA, is to acquire Exelead, a US-based biopharmaceutical CDMO for around US$780m in cash. The acquisition will strengthen the CDMO offering for mRNA of Merck’s life science business. Exelead specialises in complex injectable formulations, including Lipid Nanoparticle (LNP) based drug delivery technology which is key in mRNA…

You must be a HMI Subscriber to view this content.

Subscribe Now »